Email Alert | RSS

北京大学学报（医学版） ›› 2019, Vol. 51 ›› Issue (1): 145-150. doi: 10.19723/j.issn.1671-167X.2019.01.025

• 论著 • 上一篇    下一篇

hUTP14a在非小细胞肺癌组织中的表达

张春凤1,刘云2,陆敏3,杜晓娟4,△()   

  1. 1. 北京大学基础医学院医学遗传学系,北京　100191
    2. 北京大学医药卫生分析中心,北京　100191
    3. 北京大学基础医学院病理学系,北京　100191
    4. 北京大学基础医学院细胞生物学系,北京　100191
  • 收稿日期:2018-09-27 出版日期:2019-02-18 发布日期:2019-02-26
  • 通讯作者: 杜晓娟 E-mail:duxiaojuan100@bjmu.edu.cn
  • 基金资助:
    国家自然科学基金(81874143)

Expression of hUTP14a in non-small cell lung cancer

Chun-feng ZHANG1,Yun LIU2,Min LU3,Xiao-juan DU4,△()   

  1. 1. Department of Medical Genetics, Peking University School of Basic Medical Sciences, Beijing 100191, China
    2. Peking University Centre of Medical and Health Analysis, Beijing 100191, China
    3. Department of Pathology, Peking University School of Basic Medical Sciences, Beijing 100191, China
    4. Department of Cell Biology, Peking University School of Basic Medical Sciences, Beijing 100191, China
  • Received:2018-09-27 Online:2019-02-18 Published:2019-02-26
  • Contact: Xiao-juan DU E-mail:duxiaojuan100@bjmu.edu.cn
  • Supported by:
    Supported by the National Natural Science Foundation of China(81874143)

RICH HTML

   

PDF (PC)

摘要：

目的:hUTP14a通过促进p53和Rb降解以及增强c-Myc致癌活性促进肿瘤的发生,且在人肝癌和结直肠癌组织中表达升高。本研究检测hUTP14a在非小细胞肺癌(non-small cell lung cancer, NSCLC)组织中的表达,并分析hUTP14a的表达水平与NSCLC患者临床特征的关系。方法:收集2003年5月至2006年4月在北京大学第三医院接受手术治疗并经过组织病理学确诊的123例NSCLC患者的组织蜡块标本(鳞状细胞癌53例,腺癌70例),采用免疫组织化学染色方法分析癌组织及其邻近癌旁非肿瘤组织中hUTP14a的表达水平,应用SPSS 17.0软件的χ 2检验,以患者的性别、年龄、组织类型、肿瘤大小、分化程度以及临床分期等临床病理特征进行分组,对组间肺癌组织中hUTP14a的表达率进行比较。结果:hUTP14a在肺癌组织中的阳性表达率为37.4%(46/123),在癌旁组织中的阳性表达率为0(0/123),在肺癌组织中的表达率显著高于癌旁非肿瘤组织(P<0.001);hUTP14a在肺腺癌中的表达率为48.6%(34/70),在鳞状细胞癌中的表达率为22.6%(12/53),均显著高于相应的癌旁组织[0 (0/70),0 (0/53)]; hUTP14a在肺腺癌中的表达率显著高于在鳞状细胞癌中的表达率(48.6% vs. 22.6%,χ 2=8.66,P=0.03)。进一步分析肺鳞状细胞癌、腺癌与各临床病理特征之间的关系发现,hUTP14a在病理分期(pTNM)晚期的肺鳞状细胞癌患者肿瘤组织中的表达率显著高于pTNM早期的鳞状细胞癌患者,而与肺腺癌的pTNM分期没有显著关联性,未见hUTP14a表达与肺癌的其他临床病理特征存在关联。结论:hUTP14a在肺癌组织中特异性表达升高,而且与肺鳞状细胞癌的pTNM分期具有关联性,提示hUTP14a有可能成为早期筛查诊断NSCLC的候选标志物。

关键词: hUTP14a, 非小细胞肺癌, 免疫组织化学, 鳞状细胞癌, 腺癌

Abstract:

Objective: Human U three protein 14a (hUTP14a) facilitates tumorigenesis through promoting p53 and Rb degradation as well as enhancing c-Myc oncogenic activity. Moreover, hUTP14a expression is up-regulated in human hepatocellular cancer and colorectal cancer tissues. In this study, the expression of hUTP14a in non-small cell lung cancer (NSCLC) tissues was evaluated by immunohistochemistry staining (IHC). The relationship between hUTP14a expression levels and the clinical characteristics of the NSCLC patients were analyzed. Methods: Lung cancer tissues and the adjacent non-cancerous tissues were collected from 123 cases of NSCLC patients including 53 cases of squamous cell carcinoma (SCC) and 70 cases of adenocarcinoma (ADC), who had accepted surgical resection at Peking University Third Hospital from May 2003 to April 2006. The expression level of hUTP14a was determined by IHC in human NSCLC tissues and the adjacent non-cancerous tissues. The associations between hUTP14a expression and the clinical pathological variables including gender, age, tumor size, histological type, differentiation degree and clinical pathological stage were analyzed using the Pearson’s χ 2 test. Results: The expression rate of hUTP14a in NSCLC tissues was significantly higher than that in the non-cancerous tissues (37.4% vs. 0, P<0.001). The expressions of hUTP14a in lung ADC and SCC were 48.6% and 20.6%, respectively. The expression rate of hUTP14a in both lung ADC and SCC was significantly higher than that in the adjacent non-cancerous tissues (P<0.001). In addition, the expression rate of hUTP14a in lung ADC was significantly higher than that in SCC (χ 2=8.66, P=0.003). Furthermore, the expression rate of hUTP14a in the late pTNM stage of SCC was significantly higher than that in the early pTNM stage of SCC while hUTP14a expression level was not associated with pTNM stage of ADC. No correlation was found between hUTP14a expression and the other clinical pathologic features of the patients. Conclusion: Expression of hUTP14a was up-regulated in NSCLC tissues and was correlated with pTNM stage of SCC, suggesting that hUTP14a might possess a potential as a candidate marker for the early diagnosis screening of NSCLC.

Key words: hUTP14a, non-small-cell lung carcinoma, Immunohistochemistry, Squamous cell carcinoma, Adenocarcinoma

中图分类号: 

  • R734.2

图1

免疫组织化学染色显示hUTP14a在肺癌组织中的表达(×400)"

表1

123例肺癌患者临床特征及hUTP14a表达阳性率*"

Clinicopathologic variables hUTP14a positive rate, n (%)
Total (n=123) SCC (n=53) Adenocarcinoma (n=70)
Gender (n=123)
Male (n=74) 25 (33.8) 10 (18.9) 15 (21.4)
Female (n=49) 21 (42.9) 2 (3.8) 19 (27.1)
Age/years (n=123)
≤60 (n=55) 20 (36.4) 8 (15.1) 12 (17.1)
>60 (n=68) 26 (38.2) 4 (7.5) 22 (31.4)
Tumor size/cm (n=123)
≤3 (n=81) 32 (39.5) 7 (13.2) 25 (35.7)
>3 (n=42) 14 (33.3) 5 (9.4) 9 (12.9)
Differentiationgrade (n=112)
Poorly differentiated (n=22) 8 (36.3) 2 (3.8) 6 (8.6)
Moderately differentiated (n=78) 30 (38.5) 6 (11.3) 24 (34.3)
Highly differentiated (n=12) 4 (33.3) 2 (3.8) 2 (2.9)
pTNM stage (n=101)
Ⅰ+Ⅱ (n=64) 16 (25.0) 3 (5.7) 13 (18.6)
Ⅲ+Ⅳ (n=37) 13 (35.1) 9 (16.9) 4 (5.7)

表2

123例肺癌患者hUTP14a表达与临床病理特征之间的关系*"

Clinicopathologic variables Total (n=123), n(%) χ2 P value
hUTP14a (-) hUTP14a (+)
Gender (n=123)
Male (n=74) 49 (66.2) 25 (33.8)
Female (n=49) 28 (57.1) 21 (42.9) 1.037 0.309
Age/years (n=123)
≤60 (n=55) 35 (63.6) 20 (36.4)
>60 (n=68) 42(61.8) 26 (38.2) 0.045 0.831
Histopathology (n=123)
SCC (n=53) 41 (77.4) 12 (22.6)
Adenocarcinoma (n=70) 36 (51.4) 34 (48.6) 8.662 0.003
Tumor size/cm (n=123)
≤3 (n=81) 49 (60.5) 32 (39.5)
>3 (n=42) 28 (66.7) 14 (33.3) 0.450 0.502
Differentiation grade (n=112)
Poorly differentiated (n=22) 14 (63.6) 8 (36.4)
Moderately differentiated (n=78) 48 (61.5) 30 (38.5)
Highly differentiated (n=12) 8 (66.7) 4 (33.3) 0.132 0.936
pTNM stage (n=101)
Ⅰ+Ⅱ (n=64) 48 (75.0) 16 (25.0)
Ⅲ+Ⅳ(n=37) 24 (64.9) 13 (35.1) 1.177 0.278

表3

53例肺鳞状细胞癌患者hUTP14a表达与临床病理特征之间的关系*"

Clinicopathologic variables SCC (n=53), n(%) χ2 P value
hUTP14a (-) hUTP14a (+)
Gender (n=53)
Male (n=44) 34 (77.3) 10 (22.7)
Female (n=9) 7 (77.8) 2 (22.2) 0.001 0.974
Age/years (n=53)
≤60 (n=24) 16 (66.7) 8 (33.3)
>60 (n=29) 25 (86.2) 4 (13.8) 2.863 0.091
Tumor size/cm (n=53)
≤3 (n=27) 20 (74.1) 7 (25.9)
>3 (n=26) 21 (80.8) 5 (19.2) 0.339 0.560
Differentiation grade (n=42)
Poorly differentiated (n=10) 8 (80.0) 2 (20.0)
Moderately differentiated (n=26) 20 (76.9) 6 (23.1)
Highly differentiated (n=6) 4 (66.7) 2 (33.3) 0.388 0.824
pTNM stage (n=54)
Ⅰ+Ⅱ (n=29) 26 (89.6) 3 (10.3)
Ⅲ+Ⅳ(n=25) 17 (68.0) 8 (32.0) 3.959 0.047

表4

70例肺腺癌患者hUTP14a表达与临床病理特征之间的关系*"

Clinicopathologic variables Adenocarcinoma (n=70), n(%) χ2 P value
hUTP14a (-) hUTP14a (+)
Gender (n=70)
Male (n=30) 15 (50.0) 15 (50.0)
Female (n=40) 21 (52.5) 19 (47.5) 0.043 0.836
Age/years (n=70)
≤60 (n=31) 19 (61.3) 12 (38.7)
>60 (n=39) 17 (43.6) 22 (56.4) 2.166 0.141
Tumor size/cm (n=70)
≤3 (n=54) 29 (53.7) 25 (46.3)
>3 (n=16) 7 (43.7) 9 (56.3) 0.490 0.484
Differentiation grade (n=70)
Poorly differentiated (n=12) 6 (50.0) 6 (50.0)
Moderately differentiated (n=52) 28(53.8) 24 (46.2)
Highly differentiated (n=6) 4 (66.7) 2 (33.3) 0.463 0.793
pTNM stage (n=47)
Ⅰ+Ⅱ (n=35) 22 (62.9) 13 (37.1)
Ⅲ+Ⅳ(n=12) 7 (58.3) 5 (12.9) 0.077 0.781
[1] Zhang L, Li M, Wu N , et al. Time trends in epidemiologic cha-racteristics and imaging features of lung adenocarcinoma: a population study of 21,113 cases in China[J]. PLoS One, 2015,10(8):e0136727.
doi: 10.1371/journal.pone.0136727 pmid: 4552856
[2] 王媛媛, 毕玉, 王在翔 , 等. 山东省肺癌患者生存分析[J]. 中国卫生统计, 2018,35(1):111-116.
[3] 黄文彦, 刘凯珊 . 以新视角观察p53家族在肺癌发生及治疗中的独特作用[J]. 中国肺癌杂志, 2013,16(8):422-425.
doi: 10.3779/j.issn.1009-3419.2013.08.06
[4] 李相国, 齐景宪, 易明福 . P16、Rb和PCNA在非小细胞肺癌的表达及临床意义[J]. 临床肺科杂志, 2008,13(8):1002-1004.
doi: 10.3969/j.issn.1009-6663.2008.08.023
[5] Scheffner M, Huibregtse JM, Vierstra RD , et al. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53[J]. Cell, 1993,75(3):495-505.
doi: 10.1016/0092-8674(93)90384-3 pmid: 8221889
[6] Uchida C, Miwa S, Kitagawa K , et al. Enhanced Mdm2 activity inhibits pRB function via ubiquitin-dependent degradation[J]. EMBO J, 2005,24(1):160-169.
doi: 10.1038/sj.emboj.7600486 pmid: 15577944
[7] Sdek P, Ying H, Chang DL , et al. MDM2 promotes proteasome-dependent ubiquitin-independent degradation of retinoblastoma protein[J]. Mol Cell, 2005,20(5):699-708.
doi: 10.1016/j.molcel.2005.10.017 pmid: 16337594
[8] Hu LL, Wang JN, Liu Y , et al. A small ribosomal subunit (SSU) processome component, the human U3 protein 14A (hUTP14A) binds p53 and promotes p53 degradation[J]. J Biol Chem, 2011,286(4):3119-3128.
doi: 10.1074/jbc.M110.157842 pmid: 21078665
[9] Liu HJ, Wang JN, Liu Y , et al. Human U3 protein14a is a novel type ubiquitin ligase that binds RB and promotes RB degradation depending on a leucine-rich region[J]. Biochim Biophys Acta Mol Cell Res, 2018,1865(11 Pt A):1611-1620.
doi: 10.1016/j.bbamcr.2018.08.016
[10] Zhang JY, Ren PW, Xu D , et al. Human UTP14a promotes colorectal cancer progression by forming a positive regulation loop with c-Myc [J]. Cancer Letters, 2018, 440- 441:106-115.
doi: 10.1016/j.canlet.2018.10.010
[11] Zhang JY, Xu D, Liu ZZ , et al. Human U three protein 14a expression is increased in hepatocellular carcinoma and associated with poor prognosis[J]. Chin Med J (Engl), 2017,130(4):470-476.
doi: 10.4103/0366-6999.199839 pmid: 5324385
[12] Ma T, Lu CX, Guo YF , et al. Human U3 protein 14a plays an anti-apoptotic role in cancer cells[J]. Bio Chem, 2017,398(11):1247-1257.
[13] Groome PA, Bolejack V, Crowley JJ , et al. The IASLC Lung Cancer Staging Project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours[J]. J Thorac Oncol, 2007,2(8):694-705.
doi: 10.1097/JTO.0b013e31812d05d5 pmid: 17762335
[14] Zhang Y, Xiong Y, Yarbrough WG . ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways[J]. Cell, 1998,92(6):725-734.
doi: 10.1016/S0092-8674(00)81401-4
[15] Leduc C, Claverie P, Eymin B , et al. p14ARF promotes RB accumulation through inhibition of its Tip60-dependent acetylation[J]. Oncogene, 2006,25(30):4147-4154.
doi: 10.1038/sj.onc.1209446 pmid: 16501607
[16] Bozcuk H, Gumus A, Ozbilim G , et al. Cluster analysis of p-glycoprotein, c-erb-B2 and P53 in relation to tumor histology strongly indicates prognosis in patients with operable non-small cell lung cancer[J]. Med Sci Monit, 2005,11(6):11-20.
doi: 10.1051/medsci/2005216-7669 pmid: 15917726
[17] 张丽华, 侯振江 . p53在肺癌研究中的进展[J]. 临床肺科杂志, 2006,11(1):59-60.
doi: 10.3969/j.issn.1009-6663.2006.01.030
[1] 黄教悌,胡菁,韩博. 治疗相关神经内分泌前列腺癌机制研究与靶向治疗新进展[J]. 北京大学学报（医学版）, 2024, 56(4): 557-561.
[2] 邢念增,王明帅,杨飞亚,尹路,韩苏军. 前列腺免活检创新理念的临床实践及其应用前景[J]. 北京大学学报（医学版）, 2024, 56(4): 565-566.
[3] 颜野,李小龙,夏海缀,朱学华,张羽婷,张帆,刘可,刘承,马潞林. 前列腺癌根治术后远期膀胱过度活动症的危险因素[J]. 北京大学学报（医学版）, 2024, 56(4): 589-593.
[4] 于书慧,韩佳凝,钟丽君,陈聪语,肖云翔,黄燕波,杨洋,车新艳. 术前盆底肌电生理参数对前列腺癌根治性切除术后早期尿失禁的预测价值[J]. 北京大学学报（医学版）, 2024, 56(4): 594-599.
[5] 苏俊琪,王晓颖,孙志强. 舌鳞状细胞癌根治性切除术后患者预后预测列线图的构建与验证[J]. 北京大学学报（医学版）, 2024, 56(1): 120-130.
[6] 卢汉,张建运,杨榕,徐乐,李庆祥,郭玉兴,郭传瑸. 下颌牙龈鳞状细胞癌患者预后的影响因素[J]. 北京大学学报（医学版）, 2023, 55(4): 702-707.
[7] 朱晓娟,张虹,张爽,李东,李鑫,徐玲,李挺. 人表皮生长因子受体2低表达乳腺癌的临床病理学特征及预后[J]. 北京大学学报（医学版）, 2023, 55(2): 243-253.
[8] 沈棋,刘亿骁,何群. 肾黏液样小管状和梭形细胞癌的临床病理特点及预后[J]. 北京大学学报（医学版）, 2023, 55(2): 276-282.
[9] 李东,邸吉廷,熊焰. 程序性细胞死亡1-配体1在不同免疫组织化学染色方法的一致性比较[J]. 北京大学学报（医学版）, 2023, 55(2): 339-342.
[10] 宁博涵,张青霞,杨慧,董颖. 伴间质细胞增生、玻璃样变性及索状结构的子宫内膜样腺癌1例[J]. 北京大学学报（医学版）, 2023, 55(2): 366-369.
[11] 曹芳,钟明,刘从容. 宫体POLE突变型内膜样癌合并HPV感染相关性宫颈腺癌1例报道及文献回顾[J]. 北京大学学报（医学版）, 2023, 55(2): 370-374.
[12] 方伟岗,田新霞,解云涛. 基因多态性对中国汉族女性乳腺癌遗传易感性的影响[J]. 北京大学学报（医学版）, 2022, 54(5): 822-828.
[13] 戴翔,王飞,杜依青,宋宇轩,徐涛. 上尿路尿路上皮癌组织中脂肪因子表达与临床病理特征及预后的相关性[J]. 北京大学学报（医学版）, 2022, 54(4): 605-614.
[14] 刘圣杰,侯惠民,吕政通,丁鑫,王璐,张磊,刘明. 双极雄激素序贯免疫检查点抑制剂治疗转移性去势抵抗性前列腺癌4例[J]. 北京大学学报（医学版）, 2022, 54(4): 766-769.
[15] 周传香,周正,张晔,刘晓筱,高岩. 28例口腔基底样鳞状细胞癌的临床病理分析[J]. 北京大学学报（医学版）, 2022, 54(1): 62-67.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
ISSN 1671-167X
CN 11-4691/R
主管单位：中华人民共和国教育部
主办单位：北京大学
地址： 北京市海淀区学院路38号 北京大学医学部 《北京大学学报（医学版）》
邮编：100191
电话：010-82801551
Email： xbbjb2@bjmu.edu.cn

《北京大学学报（医学版）》
微信公众号
版权所有 © 2018 《北京大学学报（医学版）》编辑部